Orphanet: Hemophilie. orphanet Available at: http://www, orpha.net, p.18, 2016. ,
Available at: http://www.inserm.fr/thematiques/physiopathologie-metabolisme-nutrition/dossiers-dinformation/hemophilie, 2015. ,
Available at: http://www.francecoag.org/SiteWebPublic/public/stats/stats_page, pp.2-3, 2015. ,
An Overview of Hemostasis, Toxicologic Pathology, vol.257, issue.2, pp.170-179, 1993. ,
DOI : 10.1177/019262339302100209
Blood coagulation. The Lancet 355, pp.1627-1632, 2000. ,
Haemophilias A and B, The Lancet, vol.361, issue.9371, pp.1801-1809, 2003. ,
DOI : 10.1016/S0140-6736(03)13405-8
Factor VIII inhibitors: role of von Willebrand factor on the uptake of factor VIII by dendritic cells, Haemophilia, vol.109, issue.Suppl. 4, pp.61-64, 2007. ,
DOI : 10.1111/j.1365-2516.2007.01575.x
Regulation of blood coagulation, Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology, vol.1477, issue.1-2, pp.349-360, 2000. ,
DOI : 10.1016/S0167-4838(99)00266-6
Coagulation, thrombose et médecine physique, 2005. ,
Practical Understanding of Hemostasis and Approach to the Bleeding Patient in the Operating Room, Advances in Anesthesia, vol.32, issue.1, pp.1-21, 2014. ,
DOI : 10.1016/j.aan.2014.08.009
Mutating factor VIII: lessons from structure to function, Blood Reviews, vol.19, issue.1, pp.15-27, 2005. ,
DOI : 10.1016/j.blre.2004.02.003
The CDC Hemophilia A Mutation Project (CHAMP) Mutation List: A New Online Resource, Human Mutation, vol.29, issue.1, pp.2382-2392, 2013. ,
DOI : 10.1002/humu.22247
Coagulation factor VIII: structure and stability, International Journal of Pharmaceutics, vol.259, issue.1-2, pp.1-15, 2003. ,
DOI : 10.1016/S0378-5173(03)00227-8
The disappearing act of factor VIII, Haemophilia, vol.118, issue.102, pp.6-15, 2010. ,
DOI : 10.1111/j.1365-2516.2008.01864.x
Genetic diagnosis of haemophilia and other inherited bleeding disorders, Haemophilia, vol.90, issue.s3, pp.82-89, 2006. ,
DOI : 10.1182/blood-2003-01-0116
La transmission de l'hémophilie -World Federation of Hemophilia Available at: http://www.wfh.org/fr/abd/carriers/porteuses-la-transmission-de-hemophilie, p.3, 2016. ,
Available at: http://www.hemophilia.ca/fr/troubles-de-la-coagulation/hemophilie-a-et-b/l-heredite-de-lhemophilie, 2015. ,
X-chromosome inactivation and human genetic disease, Acta Paediatrica, vol.55, pp.107-112, 2002. ,
DOI : 10.1111/j.1651-2227.2002.tb03120.x
Characterization of the human factor VIII gene, Nature, vol.196, issue.5992, pp.326-330, 1984. ,
DOI : 10.1038/312326a0
Haemophilia A: database of nucleotide substitutions, deletions, insertions and rearrangements of the factor VIII gene, second edition, Nucleic Acids Research, vol.22, issue.17, pp.3511-3533, 1994. ,
DOI : 10.1093/nar/22.17.3511
Molecular Genetic Testing of Hemophilia A, Seminars in Thrombosis and Hemostasis, vol.34, issue.06, pp.491-501, 2008. ,
DOI : 10.1055/s-0028-1103360
F8 and F9 mutations in US haemophilia patients: correlation with history of inhibitor and race/ethnicity, Haemophilia, vol.59, issue.Suppl 4, pp.375-382, 2012. ,
DOI : 10.1111/j.1365-2516.2011.02700.x
Réseau France Coag: la prise en charge des patients atteints d'une maladie hémorragique héréditaire, le point en 2014, 2015. ,
Prenatal diagnosis of haemophilia in Sweden now more commonly used for psychological preparation than termination of pregnancy, Haemophilia, vol.13, issue.Suppl. 4, pp.854-858, 2014. ,
DOI : 10.1111/hae.12516
Compte-rendu de la 5ème journée du Club des biologistes en hémostase, 2013. ,
Variations physiologiques det pathologiques du facteur VIII: 'le facteur VIII dans tous ses états, BIOTRIBUNE MAG, vol.38, 2011. ,
DOI : 10.1007/s11834-011-0047-7
A critical appraisal of one-stage and chromogenic assays of factor VIII activity, Journal of Thrombosis and Haemostasis, vol.119, issue.Suppl. s2, 2015. ,
DOI : 10.1111/jth.13215
The use of the new ReFacto AF Laboratory Standard allows reliable measurement of FVIII:C levels in ReFacto AF mock plasma samples by a one-stage clotting assay, Haemophilia, vol.1, pp.958-962, 2011. ,
DOI : 10.1111/j.1365-2516.2011.02523.x
Diagnostic biologique d'une hémophilie _ cours de DES hématologie_ université de médecine de Tours, 2012. ,
L'hémophilie -encyclopédie Orphanet Grand public, Encyclopédie Orphanet Grand Public, vol.10, 2006. ,
Mortality rates and causes of death among all HIV-positive individuals with hemophilia in Canada over 21 years of follow-up, Blood, vol.108, issue.2, pp.460-464, 2006. ,
DOI : 10.1182/blood-2005-11-4407
How I treat age-related morbidities in elderly persons with hemophilia, Blood, vol.114, issue.26, pp.5256-5263, 2009. ,
DOI : 10.1182/blood-2009-07-215665
The aging patient with hemophilia, American Journal of Hematology, vol.16, issue.Suppl 4, pp.27-32, 2012. ,
DOI : 10.1002/ajh.23161
The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99, Journal of Thrombosis and Haemostasis, vol.102, issue.7, pp.1047-1054, 2004. ,
DOI : 10.1046/j.1538-7836.2004.00710.x
Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV, Blood, vol.110, issue.3, pp.815-825, 2007. ,
DOI : 10.1182/blood-2006-10-050435
Mortality and causes of death in patients with hemophilia, 1992-2001: a prospective cohort study1, Journal of Thrombosis and Haemostasis, vol.75, issue.77, pp.510-516, 1992. ,
DOI : 10.1046/j.1365-2516.1998.00179.x
The ageing patient with haemophilia, European Journal of Haematology, vol.21, issue.Suppl. 5, pp.17-22, 2015. ,
DOI : 10.1111/ejh.12497
Joint outcomes in patients with haemophilia: the importance of adherence to preventive regimens, Haemophilia, vol.8, issue.Suppl. 2, pp.1219-1227, 2009. ,
DOI : 10.1111/j.1365-2516.2009.02077.x
Haemophilic arthropathy: the importance of the earliest haemarthroses and consequences for treatment, Haemophilia, vol.130, issue.Suppl. 3, pp.4-10, 2008. ,
DOI : 10.1111/j.1365-2516.2008.01882.x
Prophylaxis in Children with Hemophilia: Evidence-Based Achievements, Old and New Challenges, Seminars in Thrombosis and Hemostasis, vol.38, issue.01, pp.79-94, 2012. ,
DOI : 10.1055/s-0031-1300954
Hemophilic arthropathy of the elbow: prophylaxis, imaging, and the role of invasive??management, Journal of Shoulder and Elbow Surgery, vol.24, issue.10, pp.1669-1678, 2015. ,
DOI : 10.1016/j.jse.2015.06.018
Réseau FranceCoag: cohorte française des patients atteints d'une maladie hémorragique héréditaire, le point en 2011, Inst. Veille Sanit, pp.1-6, 2011. ,
The natural history of HIV disease in haemophilia, Blood Reviews, vol.12, issue.3, pp.135-144, 1998. ,
DOI : 10.1016/S0268-960X(98)90011-X
Safety of coagulation factor concentrates, Haemophilia, vol.86, issue.Suppl. 1, pp.393-401, 1998. ,
DOI : 10.1046/j.1365-2516.1998.440393.x
Le traitement de l'hémophilie : des dérivés du plasma à la thérapie génique, pp.17-27, 1996. ,
Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study, Blood, vol.109, issue.11, pp.4648-4654, 2007. ,
DOI : 10.1182/blood-2006-11-056291
Développement d'inhibiteurs et prise en charge chez les patients hémophiles traités par facteur VIII ou IX d'origine plasmatique ou recombinante, pp.1-69, 2006. ,
Overview of Inhibitors, Seminars in Hematology, vol.43, issue.4, pp.3-7, 2006. ,
DOI : 10.1053/j.seminhematol.2006.03.006
BEH -Premier etat des lieux du suivi de la population hémophile en France (cohorte franceCoag, 1994-2005. Bull. Epidémiologique Hebd. 10 octobre, pp.291-298, 2006. ,
F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis, Blood, vol.119, issue.12, pp.2922-2934, 2012. ,
DOI : 10.1182/blood-2011-09-379453
Prevention and prediction of inhibitor risk, Haemophilia, vol.11, issue.128, pp.38-42, 2012. ,
DOI : 10.1111/j.1365-2516.2012.02827.x
FVIII inhibitors: pathogenesis and avoidance, Blood, vol.125, issue.13, pp.2045-2051, 2015. ,
DOI : 10.1182/blood-2014-08-535328
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4416939
Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study, Blood, vol.121, issue.20, pp.4046-4055, 2013. ,
DOI : 10.1182/blood-2012-09-457036
New early prophylaxis regimen that avoids immunological danger signals can reduce FVIII inhibitor development, Haemophilia, vol.110, issue.Suppl. 2, pp.256-262, 2010. ,
DOI : 10.1111/j.1365-2516.2009.02122.x
Non-genetic risk factors and the development of inhibitors in haemophilia: a comprehensive review and consensus report, Haemophilia, vol.7, issue.Suppl.1, pp.747-766, 2010. ,
DOI : 10.1111/j.1365-2516.2010.02231.x
The History of Hemophilia, Seminars in Thrombosis and Hemostasis, vol.40, issue.05, pp.571-576, 2014. ,
DOI : 10.1055/s-0034-1381232
Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study, Blood, vol.109, issue.11, pp.4693-4697, 2007. ,
DOI : 10.1182/blood-2006-11-056317
Factor VIII Products and Inhibitor Development in Severe Hemophilia A, New England Journal of Medicine, vol.368, issue.3, pp.231-239, 2013. ,
DOI : 10.1056/NEJMoa1208024
Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A, Blood, vol.107, issue.1, pp.46-51, 2006. ,
DOI : 10.1182/blood-2005-04-1371
Back to the future: a recent history of haemophilia treatment, Haemophilia, vol.110, issue.2, pp.10-18, 2008. ,
DOI : 10.1111/j.1538-7836.2005.01258.x
Facteurs antihémophiliques: traitement substitutif de l'hémophilie A et B, Doss. CNHIM Rev. Dévaluation Sur Médicam. XXIV, p.82, 2003. ,
Available at: http://agenceprd .ansm.sante.fr, R0236106.htm, p.30, 2016. ,
Mentions légales Octanate 50 et 100 UI/ml, 2013. ,
A solvent/detergent-treated and 15-nm filtered factor VIII: a new safety standard for plasma-derived coagulation factor concentrates, Vox Sanguinis, vol.4, issue.0, pp.327-337, 2007. ,
DOI : 10.1111/j.1423-0410.2006.00792.x
Brochure d'information Patient -Factane 200 UI/ml, 2014. ,
Process for the preparation of a concentrate from FVIII-factor von Willebrand of blood coagulation from the whole plasma ,
) - from design to clinical proof of concept, European Journal of Haematology, vol.7, issue.suppl 2, pp.369-376, 2014. ,
DOI : 10.1111/ejh.12366
Functional roles of the factor VIII B domain, Haemophilia, vol.109, issue.Suppl 2, pp.1187-1196, 2009. ,
DOI : 10.1111/j.1365-2516.2009.02026.x
Brochure promotionnelle Octanate-Success is Overcoming Challenges in life, 2007. ,
Available at: http://www.octapharma.com/en/about/production/plasma, Plasmahtml, p.13, 2016. ,
EQOFIX: a combined economic and quality-of-life study of hemophilia B treatments in France, Transfusion, vol.80, issue.Suppl 4, 2015. ,
DOI : 10.1111/trf.13016
URL : https://hal.archives-ouvertes.fr/hal-01463671
Treatment of patients with inhibitors: cost issues, Haemophilia, vol.2, issue.6, pp.397-401, 1999. ,
DOI : 10.1046/j.1365-2516.1998.00129.x
Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group, Blood, vol.102, issue.7, pp.2358-2363, 2003. ,
DOI : 10.1182/blood-2003-03-0941
Modern haemophilia care, The Lancet, vol.379, issue.9824, pp.1447-1456, 2012. ,
DOI : 10.1016/S0140-6736(11)61139-2
History of prophylaxis, Haemophilia, vol.18, issue.Suppl. 4, pp.163-165, 2013. ,
DOI : 10.1111/hae.12100
Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia, New England Journal of Medicine, vol.357, issue.6, pp.535-544, 2007. ,
DOI : 10.1056/NEJMoa067659
Considerations in individualizing prophylaxis in patients with haemophilia A. Haemoph. Off, J. World Fed. Hemoph, vol.20, pp.607-615, 2014. ,
Factor VIII/factor IX prophylaxis for severe hemophilia, Seminars in Hematology, vol.53, issue.1, 2015. ,
DOI : 10.1053/j.seminhematol.2015.10.006
Christmas Disease, BMJ, vol.2, issue.4799, pp.1378-1382, 1952. ,
DOI : 10.1136/bmj.2.4799.1378
The PRISMA statement for reporting systematic reviews and metaanalyses of studies that evaluate health care interventions: explanation and elaboration, J. Clin ,
Best Practices for Conducting Economic Evaluations in Health Care: A Systematic Review of Quality Assessment Tools, Agency for Healthcare Research and Quality, p.2012 ,
Consolidated Health Economic Evaluation Reporting Standards (CHEERS)???Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force, Value in Health, vol.16, issue.2, pp.231-250, 2013. ,
DOI : 10.1016/j.jval.2013.02.002
Development of a weighted scale to assess the quality of cost-effectiveness studies and an application to the economic evaluations of tetravalent HPV vaccine Long-term outcome of individualized prophylactic treatment of children with severe haemophilia, J. Public Health Br. J. Haematol, vol.103111, issue.112, pp.561-565, 2001. ,
A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia, Haemophilia, vol.23, issue.2, pp.689-697, 2004. ,
DOI : 10.1111/j.1538-7836.2004.00528.x
Factor VIII half-life and clinical phenotype of severe hemophilia A, Haematologica, vol.90, pp.494-498, 2005. ,
Variability in clinical phenotype of severe haemophilia: the role of the first joint bleed, Haemophilia, vol.2, issue.3, pp.438-443, 2005. ,
DOI : 10.1093/nar/26.1.216
Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study, Journal of Thrombosis and Haemostasis, vol.14, issue.3, pp.1228-1236, 2006. ,
DOI : 10.1111/j.1538-7836.2004.00653.x
A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management, Journal of Thrombosis and Haemostasis, vol.7, issue.Suppl. 3, pp.359-367, 2012. ,
DOI : 10.1111/j.1538-7836.2011.04611.x
Daily dosing prophylaxis for haemophilia: a randomized crossover pilot study evaluating feasibility and efficacy, Haemophilia, vol.17, issue.Suppl. 2, pp.855-859, 2012. ,
DOI : 10.1111/j.1365-2516.2012.02879.x
The principles of PK-tailored prophylaxis, Hämostaseologie, vol.33, pp.32-35, 2013. ,
Tailored versus standard dose prophylaxis in children with hemophilia A, Semin. Thromb. Hemost, vol.39, pp.711-722, 2013. ,
Advancing personalized care in hemophilia A: ten years’ experience with an advanced category antihemophilic factor prepared using a plasma/albumin-free method, Biologics: Targets and Therapy, vol.8, pp.115-127, 2014. ,
DOI : 10.2147/BTT.S53456
Impact of an individualized prophylaxis approach on young adults with severe hemophilia, Semin. Thromb. Hemost, vol.40, pp.785-789, 2014. ,
Rationale for individualizing haemophilia care, Blood Coagulation & Fibrinolysis, vol.26, issue.8, 2014. ,
DOI : 10.1097/MBC.0000000000000225
Individualizing factor replacement therapy in severe hemophilia ,
Individualizing prophylaxis in hemophilia: a review, Expert Review of Hematology, vol.8, issue.2, pp.237-246, 2015. ,
DOI : 10.1586/17474086.2015.1002465
Motivational effects of top-rope climbing therapy under individualized prophylaxis: a pilot study in young adults with severe haemophilia, Haemophilia, vol.21, issue.6, pp.504-507, 2015. ,
DOI : 10.1111/hae.12773
Effects of moderate-intensity physical exercise on pharmacokinetics of factor VIII and von Willebrand factor in young adults with severe haemophilia A: a pilot study, Haemophilia, vol.82, issue.Suppl. 3, pp.177-183, 2016. ,
DOI : 10.1111/hae.12869
Méthodes d'évaluation médico-économique: application à la cancérologie, Bull Cancer, pp.939-945, 2003. ,
Cost-Utility Analysis of Primary Prophylaxis versus Treatment On-Demand for Individuals with Severe Haemophilia, PharmacoEconomics, vol.3, issue.4, pp.759-774, 2002. ,
DOI : 10.2165/00019053-200220110-00005
Revisiting the cost-effectiveness of primary prophylaxis with clotting factor for the treatment of severe haemophilia A, Haemophilia, vol.42, issue.Suppl. 2, pp.881-887, 2009. ,
DOI : 10.1111/j.1365-2516.2009.02019.x
Cost–utility analysis of prophylaxis versus treatment on demand in severe hemophilia A, ClinicoEconomics and Outcomes Research, vol.3, pp.55-61, 2011. ,
DOI : 10.2147/CEOR.S16670
Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A, Haemophilia, vol.9, issue.4 ,
DOI : 10.1111/j.1365-2516.2008.01664.x
Treatment for life for severe haemophilia A- A cost-utility model for prophylaxis vs. on-demand treatment, Haemophilia, vol.11, issue.Suppl 2, pp.228-238, 2013. ,
DOI : 10.1111/hae.12121
Cost-effectiveness of prophylaxis against on-demand treatment in boys with severe hemophilia A in Iran, International Journal of Technology Assessment in Health Care, vol.9, issue.04, pp.584-587, 2009. ,
DOI : 10.1097/01.mbc.0000178830.39526.ff
Episodic versus prophylactic infusions for hemophilia A: A cost-effectiveness analysis, The Journal of Pediatrics, vol.129, issue.3, pp.424-431, 1996. ,
DOI : 10.1016/S0022-3476(96)70076-8
Secondary prophylaxis treatment versus on-demand treatment for patients with severe haemophilia A: comparisons of cost and outcomes in Taiwan, Haemophilia, vol.241, issue.Suppl 1, pp.45-54, 2011. ,
DOI : 10.1111/j.1365-2516.2010.02367.x
Cost effectiveness of haemophilia treatment: a cross-national assessment, Blood Coagulation & Fibrinolysis, vol.16, issue.7, pp.477-485, 2005. ,
DOI : 10.1097/01.mbc.0000178830.39526.ff
Assessing the effectiveness and cost-effectiveness of prophylaxis against bleeding in patients with severe haemophilia and severe von Willebrand's disease, Journal of Internal Medicine, vol.8, issue.6, pp.515-522, 1998. ,
DOI : 10.1046/j.1365-2141.1996.420960.x
Treatment for life for severe haemophilia A- A cost-utility model for prophylaxis vs. on-demand treatment, Haemophilia, vol.11, issue.Suppl 2, pp.228-238, 2013. ,
DOI : 10.1111/hae.12121
EQOFIX: a combined economic and quality-of-life study of hemophilia B treatments in France, Transfusion, vol.80, issue.Suppl 4, pp.1787-1797, 2015. ,
DOI : 10.1111/trf.13016
URL : https://hal.archives-ouvertes.fr/hal-01463671
Methods for the economic evaluation of health care programmes ,
A comparison of HAS & NICE guidelines for the economic evaluation of health technologies in the context of their respective national health care systems and cultural environments, Journal of Market Access & Health Policy, vol.11, issue.1, 2015. ,
DOI : 10.3402/jmahp.v3.24966
Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B, Journal of Internal Medicine, vol.23, issue.3, pp.25-32, 1992. ,
DOI : 10.1111/j.1365-2796.1992.tb00546.x
Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A, Journal of Thrombosis and Haemostasis, vol.10, issue.Suppl. 4, pp.413-420, 2009. ,
DOI : 10.1111/j.1538-7836.2008.03270.x
Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens, Journal of Thrombosis and Haemostasis, vol.8, issue.Suppl. 1, pp.269-275, 2010. ,
DOI : 10.1111/j.1538-7836.2009.03703.x
Plasma and albumin-free recombinant factorVIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients, Journal of Thrombosis and Haemostasis, vol.3, issue.8, pp.1319-1326, 2008. ,
DOI : 10.1111/j.1538-7836.2008.03032.x
Analyse pharmacocinétique de population, Médecine Thérapeutique, vol.11, pp.212-218, 2005. ,
La pharmacocinétique de population, aspects fondamentaux, Lett. Pharmacol, vol.17, pp.97-102, 2003. ,
Individualizing prophylaxis in hemophilia: a review, Expert Review of Hematology, vol.8, issue.2, pp.237-246, 2015. ,
DOI : 10.1586/17474086.2015.1002465
Rationale for individualizing haemophilia care, Blood Coagulation & Fibrinolysis, vol.26, issue.8, pp.0-00, 2014. ,
DOI : 10.1097/MBC.0000000000000225
Health economic models in hemophilia A and utility assumptions from a clinician's perspective, Pediatric Blood & Cancer, vol.12, issue.10, pp.1826-1831, 2015. ,
DOI : 10.1002/pbc.25543
Efficacy and safety of BAY 81-8973, a full-length recombinant factor VIII: results from the LEOPOLD I trial, Haemophilia, vol.4, issue.Suppl. 3, 2016. ,
DOI : 10.1111/hae.12952
Paper: Source of Factor VIII Replacement (PLASMATIC OR RECOMBINANT) and Incidence of Inhibitory Alloantibodies in Previously Untreated Patients with Severe Hemophilia a: The Multicenter Randomized Sippet Study Available at: https://ash.confex.com/ash, p.3, 2015. ,
Bayesian Estimation of Pharmacokinetic Parameters in Children and Adolescents with Severe Hemophilia: A Single Center Experience, Blood, vol.126, pp.3534-3534, 2015. ,
Available at: http://advatepro.com/global/haemophilia-patient-tools/mypkfit-pk-dosing-tool, p.3, 2016. ,